Eaton Vance Management reduced its stake in Anika Therapeutics Inc. (NASDAQ:ANIK) by 25.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,013 shares of the company’s stock after selling 2,000 shares during the period. Eaton Vance Management’s holdings in Anika Therapeutics were worth $323,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Prudential Financial Inc. increased its stake in shares of Anika Therapeutics by 4.9% in the first quarter. Prudential Financial Inc. now owns 35,880 shares of the company’s stock valued at $1,605,000 after buying an additional 1,680 shares during the period. HL Financial Services LLC increased its stake in shares of Anika Therapeutics by 10.1% in the second quarter. HL Financial Services LLC now owns 46,631 shares of the company’s stock valued at $2,502,000 after buying an additional 4,283 shares during the period. Adams Diversified Equity Fund Inc. purchased a new stake in shares of Anika Therapeutics during the second quarter valued at approximately $483,000. California Public Employees Retirement System increased its stake in shares of Anika Therapeutics by 3.3% in the second quarter. California Public Employees Retirement System now owns 92,600 shares of the company’s stock valued at $4,968,000 after buying an additional 3,000 shares during the period. Finally, Bogle Investment Management L P DE increased its stake in shares of Anika Therapeutics by 118.1% in the first quarter. Bogle Investment Management L P DE now owns 110,969 shares of the company’s stock valued at $4,962,000 after buying an additional 60,087 shares during the period. Institutional investors own 77.85% of the company’s stock.
Shares of Anika Therapeutics Inc. (NASDAQ:ANIK) traded up 3.80% during mid-day trading on Friday, hitting $47.85. 236,947 shares of the stock were exchanged. Anika Therapeutics Inc. has a 12 month low of $31.15 and a 12 month high of $54.96. The stock’s 50 day moving average is $47.90 and its 200-day moving average is $47.94. The stock has a market cap of $707.08 million, a PE ratio of 20.89 and a beta of 1.50.
Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings data on Wednesday, July 27th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.13. The firm earned $26.60 million during the quarter, compared to the consensus estimate of $24.75 million. Anika Therapeutics had a return on equity of 17.24% and a net margin of 33.77%. The firm’s quarterly revenue was up 16.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.51 earnings per share. On average, analysts anticipate that Anika Therapeutics Inc. will post $2.00 EPS for the current year.
Separately, Zacks Investment Research raised shares of Anika Therapeutics from a “hold” rating to a “strong-buy” rating and set a $58.00 price objective on the stock in a research report on Monday, August 1st.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.
Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).
Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.